No Data
Inception Fertility Celebrates Tennessee's IVF Protection Bill
Prelude Therapeutics Presents Preclinical Data on First-in-Class SMARCA2 and Selective KAT6A Degraders at AACR Annual Meeting
Prelude Announces Presentations at 2025 AACR Annual Meeting
Prelude Therapeutics: Solid Financial Position and Promising Clinical Catalysts Amidst Risks
Prelude Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket